Meeting
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
Authors
Tongyu Lin
Cancer Center Sun Yat Sen University, Guangzhou, China
Tongyu Lin , Fushen Sha , He Huang , Zhao Wang , Suxia Lin , Xueying Li , Huangming Hong , Xiaojie Fang , Fangfang Li , Chen Peng , Quanguang Ren , Limei Zhang , Qing Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7553)
DOI
10.1200/JCO.2018.36.15_suppl.7553
Abstract #
7553
Poster Bd #
190
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2021 ASCO Annual Meeting
Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Johannes Düll
Poster
2020 ASCO Virtual Scientific Program
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
First Author: Luis De La Cruz Merino Sr.
Poster
2015 ASCO Annual Meeting
A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.
First Author: L. Elizabeth Budde